Literature DB >> 22862288

Long-term perturbation of spine plasticity results in distinct impairments of cognitive function.

Jon-Eric Vanleeuwen1, Peter Penzes.   

Abstract

Dendritic spines serve as the post-synaptic structural component of synapses. The structure and function of dendritic spines are dynamically regulated by a number of signaling pathways and allow for normal neural processing, whereas aberrant spine changes are thought to contribute to cognitive impairment in neuropsychiatric and neurodegenerative disorders. However, spine changes within different brain regions and their contribution to specific cognitive functions, especially later in adulthood, is not well understood. In this study, we used late-adult KALRN-deficient mice as a tool to investigate the vulnerability of different cognitive functions to long-term perturbations in spine plasticity in different forebrain regions. We found that in these mice, loss of one or both copies of KALRN lead to genotype and brain region-dependent reductions in spine density. Surprisingly, heterozygote and knockout mice showed differential impairments in cognitive phenotypes, including working memory, social recognition, and social approach. Correlation analysis between the site and magnitude of spine loss and behavioral alterations suggests that the interplay between brain regions is critical for complex cognitive processing and underscores the importance of spine plasticity in normal cognitive function. Long-term perturbation of spine plasticity results in distinct impairments of cognitive function. Using genetically modified mice deficient in a central regulator of spine plasticity, we investigated the brain region-specific contribution of spine numbers to various cognitive functions. We found distinct cognitive functions display differential sensitivity to spine loss in the cortex and hippocampus. Our data support spines as neuronal structures important for cognition and suggest interplay between brain regions is critical for complex cognitive processing.
© 2012 The Authors Journal of Neurochemistry © 2012 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22862288      PMCID: PMC3493825          DOI: 10.1111/j.1471-4159.2012.07899.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  50 in total

Review 1.  Dendritic spine pathology: cause or consequence of neurological disorders?

Authors:  John C Fiala; Josef Spacek; Kristen M Harris
Journal:  Brain Res Brain Res Rev       Date:  2002-06

2.  Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components.

Authors:  Ying-Jiun J Chen; Madeleine A Johnson; Michael D Lieberman; Rose E Goodchild; Scott Schobel; Nicole Lewandowski; Gorazd Rosoklija; Ruei-Che Liu; Jay A Gingrich; Scott Small; Holly Moore; Andrew J Dwork; David A Talmage; Lorna W Role
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

3.  Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory.

Authors:  I M Mansuy; M Mayford; B Jacob; E R Kandel; M E Bach
Journal:  Cell       Date:  1998-01-09       Impact factor: 41.582

Review 4.  Dendritic spine pathology in neuropsychiatric disorders.

Authors:  Peter Penzes; Michael E Cahill; Kelly A Jones; Jon-Eric VanLeeuwen; Kevin M Woolfrey
Journal:  Nat Neurosci       Date:  2011-03       Impact factor: 24.884

5.  Neuronal basis of age-related working memory decline.

Authors:  Min Wang; Nao J Gamo; Yang Yang; Lu E Jin; Xiao-Jing Wang; Mark Laubach; James A Mazer; Daeyeol Lee; Amy F T Arnsten
Journal:  Nature       Date:  2011-07-27       Impact factor: 49.962

6.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.

Authors:  L Holcomb; M N Gordon; E McGowan; X Yu; S Benkovic; P Jantzen; K Wright; I Saad; R Mueller; D Morgan; S Sanders; C Zehr; K O'Campo; J Hardy; C M Prada; C Eckman; S Younkin; K Hsiao; K Duff
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

7.  Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system.

Authors:  Claudia S Barros; Barbara Calabrese; Pablo Chamero; Amanda J Roberts; Ed Korzus; Kent Lloyd; Lisa Stowers; Mark Mayford; Shelley Halpain; Ulrich Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-24       Impact factor: 11.205

8.  Under-expression of Kalirin-7 Increases iNOS activity in cultured cells and correlates to elevated iNOS activity in Alzheimer's disease hippocampus.

Authors:  HyeSook Youn; Inhae Ji; Hanlee P Ji; William R Markesbery; Tae H Ji
Journal:  J Alzheimers Dis       Date:  2007-11       Impact factor: 4.472

9.  genetic overexpression of NR2B subunit enhances social recognition memory for different strains and species.

Authors:  Stephanie A Jacobs; Joe Z Tsien
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

10.  Coordination of synaptic adhesion with dendritic spine remodeling by AF-6 and kalirin-7.

Authors:  Zhong Xie; Huzefa Photowala; Michael E Cahill; Deepak P Srivastava; Kevin M Woolfrey; Cassandra Y Shum; Richard L Huganir; Peter Penzes
Journal:  J Neurosci       Date:  2008-06-11       Impact factor: 6.167

View more
  10 in total

1.  δ-Catenin Regulates Spine Architecture via Cadherin and PDZ-dependent Interactions.

Authors:  Li Yuan; Eunju Seong; James L Beuscher; Jyothi Arikkath
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

2.  Kalirin-7 prevents dendritic spine dysgenesis induced by amyloid beta-derived oligomers.

Authors:  Zhong Xie; Lauren P Shapiro; Michael E Cahill; Theron A Russell; Pascale N Lacor; William L Klein; Peter Penzes
Journal:  Eur J Neurosci       Date:  2019-01-20       Impact factor: 3.386

Review 3.  KALRN: A central regulator of synaptic function and synaptopathies.

Authors:  Euan Parnell; Lauren P Shapiro; Roos A Voorn; Marc P Forrest; Hiba A Jalloul; Daniel D Loizzo; Peter Penzes
Journal:  Gene       Date:  2020-11-13       Impact factor: 3.688

Review 4.  Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.

Authors:  Arne W Mould; Noura Al-Juffali; Annette von Delft; Paul E Brennan; Elizabeth M Tunbridge
Journal:  CNS Drugs       Date:  2021-12-20       Impact factor: 5.749

Review 5.  Abnormal kalirin signaling in neuropsychiatric disorders.

Authors:  Christine Remmers; Robert A Sweet; Peter Penzes
Journal:  Brain Res Bull       Date:  2013-12-12       Impact factor: 4.077

6.  Molecular mechanisms of dendrite morphogenesis.

Authors:  Jyothi Arikkath
Journal:  Front Cell Neurosci       Date:  2012-12-28       Impact factor: 5.505

7.  Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder.

Authors:  D Arion; J P Corradi; S Tang; D Datta; F Boothe; A He; A M Cacace; R Zaczek; C F Albright; G Tseng; D A Lewis
Journal:  Mol Psychiatry       Date:  2015-01-06       Impact factor: 15.992

8.  Abnormal dendritic calcium activity and synaptic depotentiation occur early in a mouse model of Alzheimer's disease.

Authors:  Yang Bai; Miao Li; Yanmei Zhou; Lei Ma; Qian Qiao; Wanling Hu; Wei Li; Zachary Patrick Wills; Wen-Biao Gan
Journal:  Mol Neurodegener       Date:  2017-11-14       Impact factor: 14.195

9.  Reduced HGF/MET Signaling May Contribute to the Synaptic Pathology in an Alzheimer's Disease Mouse Model.

Authors:  Jing Wei; Xiaokuang Ma; Antoine Nehme; Yuehua Cui; Le Zhang; Shenfeng Qiu
Journal:  Front Aging Neurosci       Date:  2022-07-12       Impact factor: 5.702

10.  Exome sequencing discloses KALRN homozygous variant as likely cause of intellectual disability and short stature in a consanguineous pedigree.

Authors:  Periklis Makrythanasis; Michel Guipponi; Federico A Santoni; Maha Zaki; Mahmoud Y Issa; Muhammad Ansar; Hanan Hamamy; Stylianos E Antonarakis
Journal:  Hum Genomics       Date:  2016-07-16       Impact factor: 4.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.